Abstract 6057
Background
Streamlining oncology (Onc) and specialist palliative care (SPC) into integrated patient (pt) care is increasingly a gold standard of optimized cancer care. The ways that integrated Onc/SPC manifests in clinical practice may change over time. Little is known about factors that drive evolution in integrated care practices.
Methods
From a pt’s first appointment with outpatient SPC, all visits were chronologically color coded for Onc, SPC, and Neutral (e.g. emergency) or joint visits (Onc/SPC same day). Visual Graphic Analysis revealed 4 patterns of integration (Onc only; SPC only; CONCurrent: permanent exchange of Onc and SPC, ≥5 switches, joint visits; SEGmented: alternating periods of Onc or SPC, <4 switches), independent researchers approved reliability of patterns definitions. Data from 2006-2009 (presented 34-ESMO 2009) were compared with 2016-2017. Explanatory factors for patterns evolution were derived from multi-professional, consensual discussion reviewing descriptive statistics (e.g. impact of inpt admission on patterns, pattern stability over 3 months intervals, anticancer treatment administered by SPC, pt characteristics) and further explored in the data.
Results
345 pts from 2006-09 and 64 from 2016 met eligibility criteria and were included. CONC occurred in 18% in 2006-09 and 45% in 2016 (Χ2 (1, N = 409) = 22.66, p < .001)], and 14% vs 50% remained in the CONC pattern comparing 3 months intervals. Elimination of inpt visits left 3/4 of patterns unchanged. A double-boarded Onc/SPC physician saw 94% of pts in the 2016 sample and prescribed systemic anticancer treatment in > 1/3 of these visits, 77% of these pts were in the CONC Pattern. Joint Onc/SPC visits were increasing over time, also (bi-)weekly alternating visits by Onc and SPC (double-boarded). Pts of CONC had complex and high needs for palliative interventions, were in phase I studies, or refused standard anticancer treatment, but accepted later.
Conclusions
Concurrent Onc/SPC is an increasing and consistent pattern, not explained by mere bed availability. Prescribing anticancer therapy by a double-boarded physician may foster integration. Further research may determine how CONC affects pt outcomes and the influence of pt and physicians’ characteristics.
Clinical trial identification
Legal entity responsible for the study
Cantonal Hospital St.Gallen.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract